title: In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy.
abstract: The histopathological hallmark of multiple system atrophy is the appearance of intracellular inclusion bodies, named glial cytoplasmic inclusions, which are mainly composed of alpha-synuclein fibrils. In vivo visualization of alpha-synuclein deposition should be used for the diagnosis and assessment of therapy and severity of pathological progression in multiple system atrophy. Because 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole could stain alpha-synuclein-containing glial cytoplasmic inclusions in post-mortem brains, we compared the carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography findings of eight multiple system atrophy cases to those of age-matched normal controls. The positron emission tomography data demonstrated high distribution volumes in the subcortical white matter (uncorrected P < 0.001), putamen and posterior cingulate cortex (uncorrected P < 0.005), globus pallidus, primary motor cortex and anterior cingulate cortex (uncorrected P < 0.01), and substantia nigra (uncorrected P < 0.05) in multiple system atrophy cases compared to the normal controls. They were coincident with glial cytoplasmic inclusion-rich brain areas in multiple system atrophy and thus, carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography is a promising surrogate marker for monitoring intracellular alpha-synuclein deposition in living brains.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Tohoku University, Sendai, 980-8574 Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeda
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Okamura
authors.forename: Manabu
authors.initials: M
authors.lastname: Tashiro
authors.forename: Takafumi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Shozo
authors.initials: S
authors.lastname: Furumoto
authors.forename: Michiko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Naoto
authors.initials: N
authors.lastname: Sugeno
authors.forename: Toru
authors.initials: T
authors.lastname: Baba
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Miki
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Mori
authors.forename: Koichi
authors.initials: K
authors.lastname: Wakabayashi
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Funaki
authors.forename: Ren
authors.initials: R
authors.lastname: Iwata
authors.forename: Shoki
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fukuda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Arai
authors.forename: Yukitsuka
authors.initials: Y
authors.lastname: Kudo
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yanai
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Itoyama
mesh_terms: D001583:Benzoxazoles; D001921:Brain / Q000378:metabolism*; D002250:Carbon Radioisotopes; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000000981:diagnostic imaging* / Q000378:metabolism*; D049268:Positron-Emission Tomography / Q000379:methods*; D013844:Thiazoles; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: C516779:2-(2-(2-dimethylaminothiazol-5-yl)ethenyl)-6-(2-(fluoro)ethoxy)benzoxazole; D001583:Benzoxazoles; D002250:Carbon Radioisotopes; D013844:Thiazoles; D051844:alpha-Synuclein